Treatment of Anterior Uveitis in Juvenile Idiopathic Arthritis–Associated Iridocyclitis or Behçet’s Disease

Clinical scenario

Anterior uveitis arising in the setting of juvenile idiopathic arthritis (JIA)-associated iridocyclitis or Behçet’s disease is a clinically distinct subset. These systemic inflammatory conditions create a different risk profile and treatment need compared with routine acute anterior uveitis.

Corticosteroid therapy is generally not indicated in most acute anterior uveitis cases — but JIA-associated iridocyclitis and Behçet’s disease are recognised exceptions where it has an established role.

Treatment approach

This scenario calls for a more aggressive and more prolonged corticosteroid approach than would be applied in standard anterior uveitis. The extent of that approach is shaped by the degree and duration of inflammation, prior uveitis history, and the risk of structural damage.

The complete regimen structure, clinical decision points, and sequencing are detailed in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4103/0301-4738.58468

They are usually not used in acute anterior uveitis except in a few cases like JIA-associated iridocyclitis and Behcet’s disease.

Traumatic iritis does not require extensive treatment whereas juvenile rheumatoid arthritis requires more aggressive and more prolonged treatment, the further decision regarding the aggressiveness of therapy should also be based on the degree of inflammation, duration of inflammation, history of previous uveitis and how was the response to treatment, risk of structural damage and response to initial treatment.

View source ↗